34562-97-5

Basic information

• Product Name: Pikamilone
• Synonyms: PIKAMILONE HYDROCHLORIDE;NICOTINOYL-GABA;N-(3-CARBOXYPROPYL) NICOTINAMIDE;4-[(PYRIDIN-3-YLCARBONYL)AMINO]BUTANOIC ACID;4-(NICOTINAMIDO)BUTANOIC ACID;4-(3-PYRIDYLCARBOXAMIDO)BUTYRIC ACID;4-[(3-PYRIDINYLCARBONYL)AMINO]BUTANOIC ACID;Pikamiline
• CAS NO: 34562-97-5
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.21
• EINECS: 1308068-626-2
• Product Categories: Heterocycles;Chemistry;API;Other APIs
• Mol File: 34562-97-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 211.0 to 215.0 °C
• Boiling Point: 522.4 °C at 760 mmHg
• Flash Point: 269.8 °C
• Appearance: white crystalline powder
• Density: 1.245
• Vapor Pressure: 9.65E-12mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly)
• PKA: 4.60±0.10(Predicted)
• CAS DataBase Reference: Pikamilone(CAS DataBase Reference)
• NIST Chemistry Reference: Pikamilone(34562-97-5)
• EPA Substance Registry System: Pikamilone(34562-97-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 34562-97-5(Hazardous Substances Data)

Usage

Description

Pikamilone is a drug having a central (vegetotropic and vascular) and peripheral (vasodilating) mechanisms of action.

Clinical Use

Pikamilone treatment of benign prostatic hyperplasiaPikamilone is an original drug of Russian produce having a central (vegetotropic and vascular) and peripheral (vasodilating) mechanisms of action. The drug was tried as monotherapy in elderly patients with benign prostatic hyperplasia who had symptoms of the lower urinary tracts to estimate its effect on local and general mechanisms of nervous and vascular regulation of detruzor function in infravesical obstruction. https://pubmed.ncbi.nlm.nih.gov/11150159/

Uses

Nicotinoyl-γ-aminobutyric Acid is a pro-drug of γ-Aminobutyric Acid (A602920). Studies show that Nicotinoyl-γ-aminobutyric Acid is involved in the regulation of the processes in the brain of streptozotocin-induced diabetic rats.

InChI:InChI=1/C10H12N2O3.Na/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8;/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14);/q;+1/p-1

Upstream product

• 553-53-7 Nicotinic acid hydrazide 
• 56-12-2 4-amino-n-butyric acid 
• 24690-42-4 p-Nitrophenyl nicotinate 
• 20260-53-1 pyridine-3-carbonyl chloride hydrochloride 
• 121667-28-5 nicotinoyl chloride 
• 59-67-6 nicotinic acid 
• 10400-19-8 3-pyridinecarbonyl chloride 
• 34562-98-6 N-Nicotinoyl-γ-aminobuttersaeure-ethylester 

Downstream Products

• 75319-77-6 p-nitrophenyl 4-nicotinamidobutyrate 
• 59-67-6 nicotinic acid 
• 56-12-2 4-amino-n-butyric acid 
• 1316665-23-2 4-[(pyridine-3-carbonyl)amino]butyric acid 4-allyl-2-methoxyphenyl ester 

Relevant articles and documents

Evaluation of isonicotinoyl-γ-aminobutyric acid (GABA) nicotinoyl-GABA as pro-drugs of GABA

-

COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of migraine and neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, Post Herpetic Neuralgia, Acute and Chronic Pain, Alzheimer's disease, Creutzfeld Disease, familial amyloid polyneuropathy, parkinson's disease, fibromyalgia syndrome.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPATHIC PAIN

The invention relates to the compounds of formula (I), formula (II), formula (III) and formula (IV) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), formula (II), formula (III) or formula (IV) and methods for the treatment of neuropathic pain may he formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neuralgia, severe pain, chronic pain, chemotherapy induced pain, neuropathic pain, post herpetic neuralgia, neuralgia, motor neurone disease, diabetic neuropathy, postherpetic neuralgia, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, cancer pain and lower back pain.